Recent performance context for Ligand Pharmaceuticals (LGND)

Without a specific news event driving headlines today, Ligand Pharmaceuticals (LGND) still gives investors some fresh data points to consider, from recent share performance to reported revenue and net income figures.

At a share price of $237.00, Ligand Pharmaceuticals has shown solid momentum, with a 17.38% 90 day share price return and a 123.61% 1 year total shareholder return suggesting sentiment has been improving over both shorter and longer horizons.

If this kind of momentum has your attention, it could be a good moment to see what else is moving in healthcare related AI and biotech by reviewing 39 healthcare AI stocks

With the stock trading at $237.00 and current metrics pointing to a potential discount to some valuation estimates, the key question is whether Ligand Pharmaceuticals is genuinely undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 14.6% Undervalued

With Ligand Pharmaceuticals last closing at $237.00 against a narrative fair value of $277.60, the most followed storyline in the market frames the stock as trading at a meaningful discount while hinging heavily on its royalty engine.

Strong revenue and earnings growth are expected as Ligand broadens its high margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long term cash flow predictability.

Want to see what is powering that royalty story? The fair value hinges on specific growth assumptions, shifting margins, and a richer earnings multiple. Curious which ingredients matter most here.

Result: Fair Value of $277.60 (UNDERVALUED)

However, that royalty story can change quickly if drug pricing pressure bites harder than analysts assume, or if key assets like Filspari underperform against current expectations.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle On Valuation

The narrative fair value of $277.60 paints Ligand Pharmaceuticals as 14.6% undervalued, but the current P/E of 30.9x tells a different story. It is roughly double the US Pharmaceuticals industry average of 15.3x and sits well above a fair ratio of 20.6x. This implies less room for error if growth or margins come in below expectations.

For investors comparing this premium P/E to peers and that lower fair ratio, the key question is whether the royalty engine and forecast earnings justify paying up today or whether it makes sense to wait for the valuation to edge closer to where the fair ratio suggests the market could move, especially if sentiment cools.

Next Steps

If the mixed signals around valuation and growth are raising questions, treat this as a cue to move quickly and test the story against hard numbers for yourself. To see exactly what investors are optimistic about right now, take a closer look at the 3 key rewards.

Looking for more investment ideas?

If this story has you thinking bigger than a single stock, now is the time to widen your watchlist and uncover opportunities other investors might miss.

• Spot potential value plays early by scanning 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying businesses.
• Prioritize resilience by reviewing 64 resilient stocks with low risk scores that score well on financial strength, earnings stability, and lower overall risk profiles.
• Go hunting for overlooked opportunities using the screener containing 22 high quality undiscovered gems that pair solid financials with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.